Myeloproliferative Neoplasms
Specialty Channel

Featured Article
When initiated early in the course of the disease, decitabine with or without ruxolitinib has shown clinical benefit in patients with advanced phases of MPNs.
Study findings lead experts to recommend against the use of serum procalcitonin (PCT) as a disease biomarker in patients with MPNs.
True or False: The addition of azacitidine to eprenetapopt led to significantly low rates of response and remission in a study of patients with TP53-mutant MDS and oligoblastic AML.
Is there a significant link between serum ferritin level and fibrosis in older patients with MF?
Study findings showed that vedolizumab 300 mg was tolerable and led to low incidence of overall and lower-intestinal aGVHD in patients who undergo allo-HSCT.
Study findings suggest that eprenetapopt plus azacitidine is well-tolerated and leads to high rates of response and remission in patients with TP53-mutant MDS and oligoblastic AML.
Researchers have observed a significant link between serum ferritin level and fibrosis in older patients with MF.
True or False: A long-term survival advantage has been demonstrated with allogeneic HCT in certain patients with MF, at the expense of possible early death.
Which combo regimen did the PHAZAR trial confirm as being well-tolerated with comparable safety for patients with advanced-phase MPN/post-MPN AML?

News

When initiated early in the course of the disease, decitabine with or without ruxolitinib has shown clinical benefit in patients with advanced phases of MPNs.
Study findings lead experts to recommend against the use of serum procalcitonin (PCT) as a disease biomarker in patients with MPNs.
Study findings showed that vedolizumab 300 mg was tolerable and led to low incidence of overall and lower-intestinal aGVHD in patients who undergo allo-HSCT.
Study findings suggest that eprenetapopt plus azacitidine is well-tolerated and leads to high rates of response and remission in patients with TP53-mutant MDS and oligoblastic AML.

Interactive Features

True or False: The addition of azacitidine to eprenetapopt led to significantly low rates of response and remission in a study of patients with TP53-mutant MDS and oligoblastic AML.
Is there a significant link between serum ferritin level and fibrosis in older patients with MF?
True or False: A long-term survival advantage has been demonstrated with allogeneic HCT in certain patients with MF, at the expense of possible early death.
Which combo regimen did the PHAZAR trial confirm as being well-tolerated with comparable safety for patients with advanced-phase MPN/post-MPN AML?
Stay in the know.
OncNet Newsletter